Regulators set parameters to investigate link between H1N1 vaccine and narcolepsy
This article was originally published in Scrip
Executive Summary
Next week, the European Medicines Agency's scientific committee, the CHMP, which represents the EU's 27 drug regulatory agencies, will decide how best to go about investigating the potential link between GlaxoSmithKline's adjuvanted H1N1 vaccine Pandemrix and narcolepsy, following adverse drug reaction (ADR) reports, mainly in Finland, France and Sweden.